A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-30
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.